Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization

Basit Öğe Kaydı
dc.contributor.authorFarsak, Bora
dc.contributor.authorGunaydin, Serdar
dc.contributor.authorYildiz, Ulku
dc.contributor.authorSari, Tamer
dc.contributor.authorZorlutuna, Yaman
dc.date.accessioned2020-06-25T18:06:37Z
dc.date.available2020-06-25T18:06:37Z
dc.date.issued2012
dc.departmentKırıkkale Üniversitesi
dc.description.abstractPurpose The use of aprotinin in cardiac surgery is associated with overriding safety concerns. Therefore, there is increased research on alternatives. This study investigated the relative benefits of strategic leukofiltration on polymer-coated extracorporeal circuits (ECC), aprotinin, and combined therapy in high-risk patients. Methods Eight hundred and seventy-five patients (Euro-SCORE 6+) undergoing coronary revascularization over a 4-year period were prospectively randomized to one of four perfusion protocols: Group 1: polymethoxyethylacrylate (PMEA)-coated circuits + leukocyte filters (n = 214); Group 2: uncoated ECC + full Hammersmith aprotinin (n = 212); Group 3: PMEA-coated ECC + leukofilters + full Hammersmith aprotinin (n = 199); and Group 4: control no treatment (n = 250). Blood samples were collected at times T1: following the induction of anesthesia; T2: following heparin administration; T3: 15 min after cardiopulmonary bypass (CPB); T4: before cessation of CPB; T5: 15 min after protamine reversal; and T6: in the intensive care unit. Results The serum interleukin-2 levels were significantly lower at T3, T4, and T5 in all study groups. C3a levels were significantly lower at T3. Creatine kinase MB and lactate levels demonstrated well-preserved myocardia in both leukofiltration groups (P < 0.05). Neutrophil CD11b/CD18 levels were significantly lower for all study groups. Postoperative bleeding and respiratory support time were lower in all study groups. Conclusion Leukofiltration on coated circuits significantly reduced bleeding and inflammatory response related to CPB with no adverse effects, and may be a possible alternative to pharmacological intervention.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s00595-011-0012-9
dc.identifier.endpage341en_US
dc.identifier.issn0941-1291
dc.identifier.issn1436-2813
dc.identifier.issue4en_US
dc.identifier.pmid22068670
dc.identifier.scopus2-s2.0-84863517239
dc.identifier.scopusqualityQ1
dc.identifier.startpage334en_US
dc.identifier.urihttps://doi.org/10.1007/s00595-011-0012-9
dc.identifier.urihttps://hdl.handle.net/20.500.12587/5280
dc.identifier.volume42en_US
dc.identifier.wosWOS:000302109000003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringeren_US
dc.relation.ispartofSurgery Today
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCardiopulmonary bypassen_US
dc.subjectAprotininen_US
dc.subjectLeukocyte reduction procedureen_US
dc.titleClinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularizationen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization.pdf
Boyut:
358.54 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu